Axon Enterprise (NASDAQ:AXON) Insider Isaiah Fields Sells 1,017 Shares

Axon Enterprise, Inc (NASDAQ:AXON) insider Isaiah Fields sold 1,017 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $480.45, for a total value of $488,617.65. Following the sale, the insider owned 56,264 shares of the company’s stock, valued at approximately $27,032,038.80. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Axon Enterprise Price Performance

Shares of NASDAQ AXON traded up $10.84 during mid-day trading on Monday, reaching $490.18. The company had a trading volume of 577,509 shares, compared to its average volume of 1,039,278. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $792.16. The firm has a market cap of $39.82 billion, a price-to-earnings ratio of 203.40, a PEG ratio of 9.02 and a beta of 1.40. The business’s 50-day simple moving average is $561.67 and its 200 day simple moving average is $488.81.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.84 by $0.04. The business had revenue of $904.39 million during the quarter, compared to analysts’ expectations of $876.42 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. Axon Enterprise’s revenue was up 35.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.12 earnings per share. On average, research analysts predict that Axon Enterprise, Inc will post 2.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its position in Axon Enterprise by 55,955.7% in the second quarter. California State Teachers Retirement System now owns 64,781,849 shares of the biotechnology company’s stock valued at $36,317,352,000 after buying an additional 64,666,282 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Axon Enterprise by 4.3% during the second quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock worth $4,672,432,000 after buying an additional 345,365 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Axon Enterprise by 8,432.6% during the second quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company’s stock worth $1,983,414,000 after buying an additional 3,496,493 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after acquiring an additional 35,544 shares during the last quarter. Finally, Sands Capital Management LLC lifted its stake in shares of Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after acquiring an additional 167,095 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

AXON has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price objective on shares of Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Citizens Jmp restated a “market outperform” rating and set a $700.00 target price on shares of Axon Enterprise in a research note on Thursday, June 25th. Piper Sandler raised their target price on Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. UBS Group lifted their price target on Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a report on Wednesday, August 5th. Fourteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $721.57.

About Axon Enterprise

Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.

The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.